Christopher Hernandez

TherOx is a part of ZOLL Medical Corporation. Based in San Jose, California, TherOx is focused on improving the treatment of heart attacks (acute myocardial infarction, or AMI). The company is commercializing SuperSaturated Oxygen (SSO2) Therapy for the sizeable AMI patient population to save hearts, improving and ultimately saving lives. SSO2 Therapy is based on the known benefits of hyperbaric oxygen treatment in improving the body’s ability to heal. SSO2 Therapy infuses superoxygenated blood to improve microvascular flow after successful percutaneous coronary intervention (PCI) and has been shown to save heart muscle by reducing infarct size. Immediately after the coronary artery has been opened by PCI, SSO2 Therapy delivers a one-time, 60-minute infusion of the patient’s superoxygenated blood to the targeted ischemic area of the heart through a small catheter. The superoxygenated blood helps reduce capillary swelling to restore blood flow to surrounding tissue and decrease infarct size. SSO2 Therapy is aligned with current guidelines for interventional cardiology procedures. SSO2 Therapy is indicated for the preparation and delivery of supersaturated oxygen to targeted ischemic regions perfused by the patient’s left anterior descending coronary artery immediately following revascularization by means of percutaneous coronary intervention (PCI) with stenting that has been completed within six hours after the onset of anterior acute myocardial infarction (AMI) symptoms caused by a left anterior descending artery infarct lesion.